Brain Metastases News and Research

RSS

AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016

AstraZeneca today reported new Phase I extended follow-up data on osimertinib in both first- and second-line treatment of patients with non-small cell lung cancer (NSCLC), at the European Lung Cancer Conference (ELCC) 2016. Late-breaker presentations reinforced the efficacy and safety profile for osimertinib previously seen in the AURA clinical trials programme.

15 Apr 2016

Gamma Knife and RapidArc equally effective at eradicating cancer in the brain

While two advanced radiosurgery approaches — Gamma Knife and RapidArc — offer different strengths, they are equally effective at eradicating cancer in the brain, say researchers at Sidney Kimmel Cancer Center.

24 Feb 2016

Alecensa (alectinib) approved for treatment of people with advanced ALK-positive NSCLC

The U.S. Food and Drug Administration today approved Alecensa (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate treatment with, another therapy called Xalkori (crizotinib).

11 Dec 2015

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

AstraZeneca today announced that the US Food and Drug Administration has approved TAGRISSO (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.

17 Nov 2015

Discovery may lead to new anti-metastasis therapies for advanced-stage brain cancer patients

It's no surprise that people enjoy warm places like Hawaii but may suffer in hostile locales such as Antarctica. A tumor suppressor gene called PTEN is similar in that it is affected by the microenvironments of certain bodily organs to which it travels.

20 Oct 2015

Rare genetic mutation could improve outcomes in NSCLC patients with brain metastases

Most patients with non-small cell lung cancer (NSCLC) that has metastasized to the brain have a dire prognosis. But Yale researchers have identified a subset of those patients with a rare genetic mutation who are living significantly longer than patients without the mutation.

16 Oct 2015

Brain metastases evolve ‘clinically actionable’ mutations

Brain metastatic disease shows branched evolution from the primary tumour, suggest preliminary findings from the largest massively parallel sequencing study of paired samples performed so far.

7 Oct 2015

Certain laboratory results can help to predict survival in patients with brain metastases

A new MedUni Vienna study conducted in the Comprehensive Cancer Centre (CCC) Vienna shows that certain laboratory results, which have previously not been used specifically for this purpose, can help to predict survival in patients with newly diagnosed brain metastases and to decide on the most appropriate treatment strategy.

26 Sep 2015

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands.

5 Aug 2015

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer.

2 Jun 2015

WBRT associated with worse cognitive function than radiosurgery, shows study

Whole Brain Radiation Therapy (WBRT) is associated with significantly worse cognitive function than radiosurgery, and should no longer be used in the adjuvant setting after radiosurgery to treat cancer patients with brain metastases, according to a large study led by a researcher at The University of Texas MD Anderson Cancer Center.

1 Jun 2015

Investigational anti-cancer agent ONT-380 shows activity against HER2+ breast cancer

Promising clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients.

1 Jun 2015

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015.

1 Jun 2015

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the presentation of data from three studies that demonstrate the utility of Caris Molecular Intelligence®, the company's panomic comprehensive tumor profiling service, in facilitating comparisons between tumors that share histological features.

1 Jun 2015

Brigatinib drug shows promise against ALK+ non-small cell lung cancer in phase I/II clinical trial

Phase I/II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK+ non-small cell lung cancer (NSCLC), with 58 of 78 ALK+ patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.

28 May 2015

Blood-thinning treatment safe for patients with brain metastases

Cancer patients with brain metastases who develop blood clots may safely receive blood thinners without increased risk of dangerous bleeding, according to a study, published online today in Blood, the Journal of the American Society of Hematology.

19 May 2015

Study analyzes outcomes of brain metastases patients following stereotactic radiosurgery

Winner of the Leksell Radiosurgery Award, Deborah C. Marshall, recently presented her research, Survival Patterns of Patients with Cerebral Metastases after Multiple Rounds of Stereotactic Radiosurgery (SRS), at the 2015 American Association of Neurological Surgeons Annual Scientific Meeting.

7 May 2015

Researchers show potential of stem cell-based therapy in treating brain-metastatic breast cancer

Investigators from Massachusetts General Hospital and the Harvard Stem Cell Institute have developed an imageable mouse model of brain-metastatic breast cancer and shown the potential of a stem-cell-based therapy to eliminate metastatic cells from the brain and prolong survival.

27 Apr 2015

SRS fails to improve survival for NSCLC brain metastases patients

Phase III trial findings suggest that carrying out stereotactic radiosurgery before chemotherapy does not improve overall survival for non-small-cell lung cancer patients with asymptomatic brain metastases compared with chemotherapy alone.

28 Jan 2015

UT Southwestern researchers find new potential target for halting tumor growth

UT Southwestern Medical Center researchers have discovered that brain tumors are capable of burning acetate for fuel, providing a new potential target for halting tumor growth.

19 Dec 2014

Brain Metastases News and Research

AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016

Gamma Knife and RapidArc equally effective at eradicating cancer in the brain

Alecensa (alectinib) approved for treatment of people with advanced ALK-positive NSCLC

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

Discovery may lead to new anti-metastasis therapies for advanced-stage brain cancer patients

Rare genetic mutation could improve outcomes in NSCLC patients with brain metastases

Brain metastases evolve ‘clinically actionable’ mutations

Certain laboratory results can help to predict survival in patients with brain metastases

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

WBRT associated with worse cognitive function than radiosurgery, shows study

Investigational anti-cancer agent ONT-380 shows activity against HER2+ breast cancer

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Brigatinib drug shows promise against ALK+ non-small cell lung cancer in phase I/II clinical trial

Blood-thinning treatment safe for patients with brain metastases

Study analyzes outcomes of brain metastases patients following stereotactic radiosurgery

Researchers show potential of stem cell-based therapy in treating brain-metastatic breast cancer

SRS fails to improve survival for NSCLC brain metastases patients

UT Southwestern researchers find new potential target for halting tumor growth

Deciphering the Microbiome with The Microsetta Initiative

Leveraging the power of automation to boost research

Automating research - solutions and best practices

Latest News